Disease relevance of MCC 478

• METHODS: A randomised, placebo controlled, dose escalation study of oral alamifovir was conducted in 66 chronic hepatitis B infected patients who were selected based on stable HBV DNA (>10(5)copies/ml), with no significant liver pathology [1].
• Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus [2].

High impact information on MCC 478

• Clinical pharmacokinetics of alamifovir and its metabolites [3].
• Although alamifovir was rapidly absorbed, there was limited systemic exposure due to its rapid hydrolysis and formation of at least three metabolites, suggesting that alamifovir acts as a prodrug [3].
• Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection [1].
• BACKGROUND/AIMS: Alamifovir is a purine nucleotide analogue prodrug that shows potent activity against wild type and lamivudine resistant hepatitis B virus in preclinical studies [1].

Analytical, diagnostic and therapeutic context of MCC 478

• They received either placebo or alamifovir at a total daily dose ranging from 2.5 to 20mg in single or divided doses for 28 days and were followed up for approximately 12 weeks after cessation of treatment [1].
• Two studies were conducted to examine the single- and multiple-dose alamifovir pharmacokinetics after oral administration in healthy males [3].
• Concentrations of alamifovir and its major metabolites were determined using liquid chromatography/tandem mass spectrometry methods [3].

References